about
Inhibition of macroautophagy triggers apoptosisConcise total synthesis of (+/-)-salinosporamide A, (+/-)-cinnabaramide A, and derivatives via a bis-cyclization process: implications for a biosynthetic pathway?Discovery and characterization of a marine bacterial SAM-dependent chlorinaseAdvances in the understanding of mechanisms and therapeutic use of bortezomibProtein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cellsTriptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expressionIdentification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data.Role of the ubiquitin proteasome system in renal cell carcinoma.Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve.Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitorsA phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancerNF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells.The docking protein p130Cas regulates cell sensitivity to proteasome inhibition.Bortezomib in kidney transplantation.Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation densityEffects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro.Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicityHDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivoA phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemiasBioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects.NOB1 is essential for the survival of RKO colorectal cancer cellsUpdate on clinical radiobiologyMicroRNAs: new biomarkers and therapeutic targets after cardiac arrest?Ubiquitin-independent proteasomal degradation during oncogenic viral infections.Breast cancer cell line MCF7 escapes from G1/S arrest induced by proteasome inhibition through a GSK-3β dependent mechanism.Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapyDifferential cell adhesion of breast cancer stem cells on biomaterial substrate with nanotopographical cues.The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discoveryCalcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activitiesQuantitative proteomic analysis revealed 4-(methylnitrosamino)-1-(3-pyridinyl)-1-butanone-induced up-regulation of 20S proteasome in cultured human fibroblast cellsUpdate on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomibSEL1L, an UPR response protein, a potential marker of colonic cell transformationRole of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to BortezomibInhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice.Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.Cancer proteomics by quantitative shotgun proteomics.
P2860
Q24338482-6FB5DC0B-6EA0-457C-97A2-8CCAD522410BQ24642621-1004FB3A-9CCA-4AA3-9693-DA7D641E7E66Q24652817-8117AB42-7BDE-4B5E-A701-DCBA896F0E24Q26849940-27473426-B290-418A-AEEB-D89B78637E17Q28475914-4C0AE72A-E05E-49C0-A579-DE00F9732D9DQ28484018-7A94C78E-D28E-4B6E-8971-3F9C2E476F20Q30983130-EA5FD235-42B8-49C5-AFF5-0D29E4648264Q33307879-066E6B4F-C93C-4A38-AD28-95E0CD425CA1Q33378628-B4F299CC-3A07-4C22-92DB-F4131F10D070Q33617012-C560313F-DD93-413C-B07B-5E3A4D80B113Q33629972-384F287E-F776-4F62-B658-2FA748F23DD8Q33946183-9451B9FD-8E6D-430E-8F7C-0F55A153D1B1Q34013972-6A31B473-0044-40B7-B26B-D2151598B3C5Q34060635-DDBC7C48-A244-4EF3-9278-23712959DB43Q34189435-A2D2A8C0-A886-4E66-A464-1EEDB6640B55Q34226021-D63179BC-41AC-4119-B71A-375710D5DA15Q34283058-3519943B-CFC1-4F37-9130-411B8B1AF93BQ34300719-80833D88-FC01-41A6-B068-873EE1C46E39Q34307050-25816686-71DA-4F91-AF29-796B26E37252Q34313670-7856F3E6-F424-4AED-AB5D-15A060F4BCB4Q34473136-1B105CE0-38C2-4FE5-8779-D36ACB1B5183Q34534191-D3E2EA14-937D-477C-B682-48EE75A77B85Q34629803-4D6F8BEF-9830-4C28-8EB9-37CF6E0B1CC8Q34685653-B4396D85-D776-4635-9C65-CF8699E3327CQ34985999-BF526FBB-58D5-49AE-A34B-939C599867C5Q34991321-7FBB4D3A-BB10-4191-A20A-DBDFC7601DC6Q35071551-CD5B12B9-3757-487E-A08F-8C9D794C3288Q35354212-1C3D9B15-6AAE-4703-A7C6-BE56B9FE65DCQ35569092-646F03B3-729D-461D-A3DF-FD96D19E5FCAQ35800503-B82B3CBD-C3C2-4E41-8874-83883B77D603Q35824491-FDE10CAE-F77B-46DD-9F38-1DB44B86CF2CQ35824929-9AB22EA5-9B57-4F00-BC79-119B29847A1AQ35849327-1C6E7998-1A11-4947-979B-74C0F9A2F2FFQ35874863-CF1AF1DF-A1F9-44F9-90BA-5964DC56619EQ35905929-EC683BEA-AB04-4EDC-BA13-3C22D0B0CF0FQ35939318-DEBCDEFC-9DC9-4DA7-89B0-4297B908F76AQ35972588-32249429-692E-4FAA-9E6A-CBAF9C1A8EFEQ36217025-022FB6EA-0AB3-4A5B-81A9-F392A8392D59Q36407085-10AB6B3D-65DA-43CC-9A3D-696E11B681B6Q36600420-E3CACCD3-5936-4523-A743-AD120A36219B
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The proteasome as a target for cancer therapy.
@ast
The proteasome as a target for cancer therapy.
@en
The proteasome as a target for cancer therapy.
@nl
type
label
The proteasome as a target for cancer therapy.
@ast
The proteasome as a target for cancer therapy.
@en
The proteasome as a target for cancer therapy.
@nl
prefLabel
The proteasome as a target for cancer therapy.
@ast
The proteasome as a target for cancer therapy.
@en
The proteasome as a target for cancer therapy.
@nl
P2093
P1476
The proteasome as a target for cancer therapy
@en
P2093
Bert O'Neil
E Claire Dees
Peter M Voorhees
P304
P407
P577
2003-12-01T00:00:00Z